RBC Capital Reiterates Outperform Rating on Ligand Pharmaceuticals Incorporated (LGND)

Market Context

Ligand Pharmaceuticals Incorporated operates in the Healthcare sector. The stock currently trades at $296.26 with a market capitalization of $3.6B. The stock has gained 147.3% over the past 52 weeks.

Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ligand Pharmaceuticals Incorporated.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Ligand Pharmaceuticals Incorporated

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 15, 2026	RBC Capital	Outperform	N/A
Jul 09, 2026	B of A Securities	Buy	N/A
Jul 08, 2026	Stifel	Buy	N/A
May 08, 2026	RBC Capital	Outperform	N/A
Apr 30, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View LGND Stock Page